Dec 02, 2018
Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH
Nov 02, 2018
Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® Plus Rituximab in Follicular Lymphoma
Oct 31, 2018
Global Non-Hodgkin Lymphoma Therapeutics Market Outlook to 2025 featuring Novartis, Merck, GSK, Bayer, Pfizer, Celgene, and many more
Oct 26, 2018
Nordic Nanovector Announces Opening of First US Site for PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma
Oct 25, 2018
Nordic Nanovector's Betalutin® Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma
Sep 11, 2018
Global B-cell non hodgkin lymphoma drugs market 2018-2022
Jul 09, 2018
Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma
Jun 21, 2018
Nordic Nanovector Announces First Patient Dosed in Pivotal PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma Patients
Jun 16, 2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Jun 15, 2018
European Hematology Association: Is RELEVANCE Relevant? Results of the Phase III Study of R2 vs R-chemo in First-line Follicular Lymphoma
Jun 13, 2018
Nordic Nanovector Announces Archer-1 Trial of Betalutin® plus Rituximab in 2L Follicular Lymphoma Approved to Start in Norway
Jun 12, 2018
Nordic Nanovector Announces Betalutin® has been Granted Fast Track Designation in the US for Follicular Lymphoma
Jun 11, 2018
Nordic Nanovector to Present Preclinical Data Demonstrating Betalutin® Reverses Resistance to Anti-CD20 Treatment in NHL Cells
Jun 03, 2018
Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma
May 25, 2018
Nordic Nanovector Updates on Clinical Trial Applications for Archer-1 and PARADIGME Trials in Norway
May 16, 2018
Forty Seven, Inc. to Present Clinical Data on 5F9, its First-in-Class CD47 Antibody, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 03, 2018
Forty Seven, Inc. Granted Fast Track Designation for 5F9 for the Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
May 01, 2018
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Mar 15, 2018
Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumor Effect of Humalutin® in Three Lymphoma Models at AACR 2018
Feb 27, 2018
Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2017: Solid Performance Through 2017, Moving Forward With Pivotal Trial